You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Updates on Nonsteroidal Mineralocorticoid Receptor Antagonists: Review of Data

To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

  1. The FDA-approved sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated which of the following in 6 outcomes trials involving people with type 2 diabetes (T2D)?
    Consistent reduction of kidney disease progression for all the agents in the class
    Heterogeneity of major adverse cardiovascular events for all agents in the class
    Reduction in risk of hospitalization for heart failure for only some of the agents in the class
  2. Which of the following is true regarding a prespecified analysis, including a kidney outcomes trial and a cardiovascular outcomes trial of a nonsteroidal mineralocorticoid receptor antagonist (MRA), in people with kidney disease and T2D?
    The analysis included approximately 4700 patients
    No impact on risk of hospitalization for heart failure
    Reduction in composite cardiovascular outcome vs placebo